# FDA Approves Generic Dapagliflozin from Alembic Pharmaceuticals The U.S. FDA has approved Alembic Pharmaceuticals Limited's generic dapagliflozin oral formulation, expanding competition in the SGLT2 inhibitor market and likely creating pricing pressure for branded alternatives. This approval is expected to increase access to the diabetes and heart failure treatment while reducing costs for patients and payers.